

## **REVIV3 PROCARE CO**

### FORM 8-K (Current report filing)

### Filed 10/13/23 for the Period Ending 10/13/23

Address 901 S. FREMONT AVE.

**UNIT 158** 

ALHAMBRA, CA, 91803

Telephone 888-638-8883

CIK 0001718500

Symbol RVIV

SIC Code 2844 - Perfumes, Cosmetics and Other Toilet Preparations

Industry Personal Products

Sector Consumer Non-Cyclicals

Fiscal Year 05/31

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

### FORM 8-K

## CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2023

	Delaware	001-38112	43-1985966
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	901 Fremont Avenue, Unit 158, Alham	bra, CA	91803
	(Address of principal executive off	ices)	(Zip Code)
	Registrant's	telephone number, including area code	e: (888) 638-8883
ovisions	S:		
ovisions		5 under the Securities Act (17 CFR 230.4 nder the Exchange Act (17 CFR 240.14a nt to Rule 14d-2(b) under the Exchange Act to Rule 13e-4(c) under the Exchange Act to Rule 13e-4(c) under the Exchange Act to Rule 13e-4(c)	425) a-12) Act (17 CFR 240.14d-2(b))
ovisions	Written communications pursuant to Rule 42 Soliciting material pursuant to Rule 14a-12 u Pre-commencement communications pursuan Pre-commencement communications pursuan registered pursuant to Section 12(b) of the Excl	5 under the Securities Act (17 CFR 230.4 nder the Exchange Act (17 CFR 240.14 at to Rule 14d-2(b) under the Exchange Act to Rule 13e-4(c) under the Exchange Act nange Act:  Trading Symbol(s)	Act (17 CFR 240.14d-2(b)) Act (17 CFR 240.13e-4(c))  Name of each exchange on which registered
visions	Written communications pursuant to Rule 42 Soliciting material pursuant to Rule 14a-12 u Pre-commencement communications pursuant Pre-commencement communications pursuant registered pursuant to Section 12(b) of the Excl	5 under the Securities Act (17 CFR 230. nder the Exchange Act (17 CFR 240.14a at to Rule 14d-2(b) under the Exchange Act to Rule 13e-4(c) under the Exchange Act ange Act:	425) 1-12) Act (17 CFR 240.14d-2(b)) Act (17 CFR 240.13e-4(c))

#### Item 2.02 Results of Operations and Financial Condition.

On October 13, 2023, Reviv3 Procare Company (the "Company") issued a press release announcing its consolidated financial results for the three months ended August 31, 2023. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

#### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits

Exhibit
---------

No.	Description
99.1	Earnings Press Release of Reviv3 Procare Company, dated October 13, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### REVIV3 PROCARE COMPANY

Date: October 13, 2023 /s/ Jeff Toghraie

Name: Jeff Toghraie

Title: Chief Executive Officer

-2-

#### REVIV3 Procare Company Reports Financial Results for the First Quarter of Fiscal Year 2024

- Net Sales (revenue) up 44.1% for the quarter ended August 31, 2023, as compared to the prior year period.
- Gross Profit (as a percentage of Net Sales) was 76.1% as compared to 77.5% in the prior year period.
- Operating expenses as a percentage of Net Sales was 73.3% compared to 72.8% in the prior year period.

LOS ANGELES, CA, October 13, 2023 (GLOBE NEWSWIRE) -- Reviv3 Procare Company ("Reviv3," "we," "us," "our," or the "Company") (OTCQB: RVIV), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the first quarter ended August 31, 2023 ("Q1").

"Reviv3 had a strong start to the fiscal year with increased product adoption and customer acquisition through our various sales channels, which resulted in a 44.1% increase in Net Sales as compared to the same period last year," remarked Monica Diaz Brickell, CFO. "During the quarter and throughout the balance of this fiscal year we are committed to furthering our financial strength through pragmatic revenue growth and a disciplined approach to managing operating costs and expenses," continued Ms. Brickell.

"Our focus during the first quarter was continued expansion of our global retail presence through the onboarding of new domestic and international vendors and distributors, which we expect to continue in the second quarter and beyond," added Jeff Toghraie, CEO. "We intend to grow our business to create long-term success for our brands and ultimately drive shareholder value and we are excited about where the business is heading," concluded Mr. Toghraie.

## REVIV3 PROCARE COMPANY AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS

		gust 31, 2023 Unaudited)	M	ay 31, 2023
ASSETS				
CURRENT ASSETS:				
Cash	\$	5,061,723	\$	4,832,682
Accounts receivable, net		455,886		417,016
Inventory, net		2,069,968		1,311,864
Prepaid expenses and other current assets		485,609		801,360
Total Current Assets		8,073,186		7,362,922
OTHER ASSETS:				
Property and equipment, net		199,561		157,463
Intangible assets, net		363,299		382,674
Right of use asset		86,111		101,845
Other assets		12,194		12,195
Goodwill	\$	2,152,215		2,152,215
Total Other Assets		2,813,380		2,806,392
				2,000,372
TOTAL ASSETS	\$	10,886,566	\$	10,169,314
LIABILITIES AND STOCKHOLDERS' EQUITY				
CURRENT LIABILITIES:				
Accounts payable	\$	1,077,005	\$	908,606
Customer deposits	Ψ	92,817	Ψ	183,688
Equipment payable, current		1,375		2,200
Contract liabilities, current		909,883		827,106
Notes payable		155,334		172,588
Due to related party		58,980		158,072
Lease Liability, current		68,558		65,824
Income Tax Liability		296,902		230,913
Other current liabilities		768,185		305,664
Total Current Liabilities		3,429,039		2,854,661
LONG TERM LIABILITIES:				
Lease liability, long term		18,650		36,752
Contract liabilities, long term		561,359		605,942
Conduct natifices, long term	_	301,339		003,942
Total Long Term Liabilities		580,009		642,694
Total Liabilities		4,009,048		3,497,355
		4,002,040		3,477,333
Commitments and contingencies		<del>_</del>		_
STOCKHOLDERS' EQUITY:				
Preferred stock, \$0.0001 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of August 31, 2023 and May 31, 2023		25,000		25,000
Common stock, \$0.0001 par value: 450,000,000 shares authorized; 117,076,949 shares issued, and outstanding as		23,000		23,000
of August 31, 2023 and May 31, 2023		11,708		11,708
Additional paid-in capital		10,153,350		10,102,243
Additional paid-in capital  Accumulated deficit		(3,312,540)		
Accumulated deficit		(3,312,340)	_	(3,466,992)
Total Stockholders' Equity		6,877,518		6,671,959
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	10,886,566	\$	10,169,314
		<u> </u>		

# REVIV3 PROCARE COMPANY AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Mo August :	
	2023	2022
Sales, net	\$ 6,106,269 \$	4,237,358
Cost of sales	1,458,703	954,704
Gross profit	4,647,566	3,282,654
OPERATING EXPENSES:		
Marketing and selling expenses	3,206,841	1,977,976
Compensation and related taxes	279,989	280,688
Professional and consulting expenses	426,775	466,450
General and administrative	560,204	358,139
Total Operating Expenses	4,473,809	3,083,253
INCOME FROM OPERATIONS	173,757	199,401
OTHER INCOME (EXPENSE):		
Gain on debt settlement	_	50,500
Other income	9,835	_
Interest income	38,493	1,837
Interest expense and other finance charges	(1,644)	(1,458)
Other Income (Expense), Net	46,684	50,879
INCOME BEFORE PROVISION FOR INCOME TAXES	220,441	250,280
Provision for income taxes	65,989	74,753
NET INCOME	<u>\$ 154,452</u> <u>\$</u>	175,527
NET INCOME PER COMMON SHARE:		
Basic	\$ 0.00 \$	0.00
Diluted	\$ 0.00	
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:		
Basic	117.076.040	102 402 140
	117,076,949	102,402,140
Diluted	372,451,949	314,223,880

# REVIV3 PROCARE COMPANY AND SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the Thr Ended Au			
		2023		2022
CASH FLOWS FROM OPERATING ACTIVITIES				
Net income (loss)	\$	154,452	\$	175,527
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		20.225		10.660
Depreciation and amortization		28,237		19,669
Bad debts		52,866		
Stock based compensation		51,107		97,283
Gain on debt forgiveness Change in operating assets and liabilities:		_		(50,500)
Accounts receivable		(91,736)		(93,901)
Inventory		(758,104)		432,998
Prepaid expenses and other current assets		315,751		(204,130)
Accounts payable and accrued expenses		168,399		52,247
Other current liabilities		438,006		296,106
Contract liabilities		38,194		82,334
		30,171		02,331
NET CASH PROVIDED BY OPERATING ACTIVITIES		397,172		807,633
CASH FLOWS FROM INVESTING ACTIVITIES				
Cash acquired on business acquisition		_		1,066,414
Purchase of property and equipment		(50,960)		(6,400)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES		(50,960)		1,060,014
CASH FLOWS FROM FINANCING ACTIVITIES				
Repayment of equipment financing		(825)		(825)
Repayment of note payable		(17,254)		(623)
Advances (payments) from a related party		(99,092)		2,732
Naturales (payments) from a rotated party		(77,072)		2,732
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		(117,171)		1,907
NET INCREASE IN CASH		229,041		1,869,554
CASH Designing of maried		4.022.602		272 721
CASH - Beginning of period		4,832,682		373,731
CASH - End of period	\$	5,061,723	\$	2,243,285
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:				
Cash paid during the period for:				
Interest	\$	1,644	\$	125
Income taxes	\$	1,011	\$	123
modic daes	Φ		Ф	
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:				
Stock issued for asset purchase agreement	\$	_	\$	4,007,480
Tangible assets (excluding cash) acquired in business combination	\$		\$	1,740,729
Intangible assets acquired in business combination	\$		\$	456,945
	Ψ			
	•		Ψ.	7 157 715
Goodwill acquired in business combination  Liabilities assumed in business combination	\$ \$		<u>\$</u>	2,152,215 1,408,823

#### **About Reviv3**

Reviv3 Procare Company (OTCQB: RVIV) is an emerging global e-commerce consumer products company. The Company is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL® brand and premium hair and skincare products under its in-house Reviv3 Procare brand - selling products in the United States, Canada, the European Union and throughout Asia. To learn more, please visit the Company's website at www.reviv3.com and, for the AXIL® brand, visit www.goaxil.com.

#### Forward-Looking Statements

This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as "expect," "intend," and "committed," among others, generally identify forward-looking statements. These forward-looking statements are based on currently available information, and management's beliefs, projections, and current expectations, and are subject to a number of significant risks and uncertainties, many of which are beyond management's control and may cause Reviv3's results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forwardlooking statements include, among other things: (i) Reviv3's ability to grow net sales as anticipated and perform in accordance with guidance; (ii) our ability to generate sufficient revenue to support Reviv3's operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives, including integrating the AXIL® brand; (iv) Reviv3's ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) the concentration of Reviv3's customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns; (vi) changes in laws or regulations in the United States and/or in other major markets, such as Asia or the European Union, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3's product costs and other costs of doing business, and reduce Reviv3's earnings; and (vi) the impact of unstable market and general economic conditions on Reviv3's business, financial condition and stock price, including inflationary cost pressures, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict and ongoing impact of COVID-19, and other downturns in the business cycle or the economy. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company's filings with the U.S. Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

#### **Investor Relations:**

Reviv3 Investor Relations Team (888) 638-8883 investors@reviv3.com